Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cabot Oil & Gas, Biogen, JOYY, and Berry Corporation and Encourages Investors to Contact the Firm
16 déc. 2020 19h00 HE
|
Bragar Eagel & Squire
NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cabot Oil & Gas, Biogen, JOYY, and Berry Corporation and Encourages Investors to Contact the Firm
09 déc. 2020 20h00 HE
|
Bragar Eagel & Squire
NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, JOYY, Berry Corporation, and Pinterest and Encourages Investors to Contact the Firm
02 déc. 2020 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Neovasc, Interface, and Biogen and Encourages Investors to Contact the Firm
24 nov. 2020 20h00 HE
|
Bragar Eagel & Squire
NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intercept Pharmaceuticals, Neovasc, Interface, and Biogen and Encourages Investors to Contact the Firm
18 nov. 2020 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Biogen, Inc. and Encourages Investors to Contact the Firm
13 nov. 2020 20h00 HE
|
Bragar Eagel & Squire
NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United...
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen, Inc. on Behalf of Biogen Stockholders and Encourages Investors to Contact the Firm
12 nov. 2020 20h00 HE
|
Bragar Eagel & Squire
NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Biogen, Inc. (NASDAQ:...
European Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application for Alzheimer's Disease
30 oct. 2020 07h00 HE
|
Biogen Inc.
If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer’s disease and to meaningfully change the course of Alzheimer’s disease CAMBRIDGE, Mass. and...
Global Neurodegenerative Disorder Therapeutics Market - Improvement in the healthcare infrastructure is likely to create new opportunity for the market
13 août 2020 10h34 HE
|
PMI
Covina, CA, Aug. 13, 2020 (GLOBE NEWSWIRE) -- The report "Global Neurodegenerative Disorder Therapeutics Market, By Indication Type (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis,...
The New England Journal of Medicine Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS
08 juil. 2020 17h01 HE
|
Biogen Inc.
Tofersen is an investigational molecule for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), the second most common genetic form of ALS, a progressive neurodegenerative diseaseFinal...